Abstract
Purpose:
Matrix metalloproteinase (MMP) 14 has been shown to promote angiogenesis, but the underlying mechanisms are poorly understood. In this study, we investigated exosomal transport of MMP14 and its target, MMP2, from corneal fibroblasts to vascular endothelial cells as a possible mechanism governing MMP14 activity in corneal angiogenesis.
Methods:
We isolated MMP14-containing exosomes from corneal fibroblasts by sucrose density gradient and evaluated exosome content and purity by Western blot analysis. We then investigated exosome transport in vitro from corneal fibroblasts to two populations of vascular endothelial cells, human umbilical vein endothelial cells (HUVECs) and calf pulmonary artery endothelial cells (CPAECs). Western blot analysis and gelatin zymography were used to determine levels of MMP14 and MMP2, respectively, in exosomal fractions derived from cultured wild-type, MMP14 enzymatic domain-deficient (MMP14Δexon4), and MMP14-null corneal fibroblasts.
Results:
Matrix metalloproteinase 14–containing exosomes isolated from corneal fibroblasts were readily taken up in vitro by HUVECs and CPAECs. We found that MMP14 was enriched in exosomal fractions of cultured corneal fibroblasts. Moreover, loss of the MMP14 enzymatic domain resulted in accumulation of pro-MMP2 protein in exosomes, whereas MMP2 was nearly undetectable in exosomes of MMP14-null fibroblasts.
Conclusions:
Our results indicate that exosomes secreted by corneal fibroblasts can transport proteins, including MMP14, to vascular endothelial cells. In addition, recruitment of MMP2 into corneal fibroblast exosomes is an active process that depends, at least in part, on the presence of MMP14. The role of exosomal MMP14 transport in corneal angiogenesis has important implications for therapeutic applications targeting angiogenic processes in the cornea.
Matrix metalloproteinases (MMPs) are a large family of zinc-dependent endopeptidases that are crucial to extracellular matrix (ECM) remodeling.
1 Matrix metalloproteinases function in the modification of essentially all components of the ECM, including collagens, proteoglycans, and fibronectins. They are also involved in modulating the activity of signaling molecules and play important roles in both normal physiology and pathological processes including neovascularization and tumor metastasis.
2–5 As such, MMPs are important potential targets for controlling such processes and in treating of a variety of pathological conditions.
Matrix metalloproteinase 14 (also known as membrane type 1 MMP, MT1-MMP) in particular is involved in many processes including wound healing, angiogenesis, inflammation, and cancer invasion and metastasis.
6–15 The importance of MMP14 is demonstrated by the deleterious effects resulting from its absence. For example, MMP14 knockout mice display an extremely disfigured phenotype as a result of inadequate collagen turnover and bone remodeling, which lead to marked deceleration in postnatal growth and, ultimately, premature death.
11,12,16 Matrix metalloproteinase 14 is known to be required for proteolysis of the ECM during the normal growth of blood vessels (angiogenesis), which allows new endothelial cells to migrate and invade tissues.
16–18 Proteolysis of the ECM is normally a highly regulated process, with MMP14 localized to discrete regions of the cell membrane.
17,19 However, this regulation is disrupted in tumors, resulting in widespread ECM remodeling by MMP14 and its targets, which allows the tumor to grow quickly and in a highly disorganized fashion, gaining access to the body's vasculature and leading to metastasis.
10 In previous studies, we demonstrated that MMP14 potentiates the angiogenic processes (including vessel invasion, increased levels of vascular endothelial growth factor [VEGF], and phosphorylation of signaling molecules) involved in fibroblast growth factor (FGF)2-induced corneal neovascularization in corneal fibroblasts in culture and in the mouse eye.
7–9,20,21 Matrix metalloproteinase 14 also activates MMP2, which further facilitates breakdown of ECM in the cornea.
22,23
Knowledge of the mechanisms underlying MMP14's actions in angiogenesis is needed for the development of therapeutics that target angiogenic processes. In the present study, we investigated whether exosomal transport between cells facilitates MMP14 activity in the cornea. Exosomes are composed of a common, characteristic set of membrane and cytosolic molecules, including tumor susceptibility gene (TSG)101, integrin β1 (ITGB1), and cytoskeletal proteins. The biochemically active components of the exosome membrane can include receptors, adhesion molecules, transporters, and enzymes, including MMPs.
24–28 We show that MMP14 and MMP2 are concentrated and enzymatically active in exosomes derived from wild-type (WT) corneal fibroblasts. We then use genetically modified cell lines to show that MMP14-containing exosomes secreted by fibroblasts are readily taken up by endothelial cells, but not as effectively taken up by fibroblasts. The mechanisms responsible for this difference are unknown but appear to be cell type specific. Finally, we show that MMP14 is necessary for MMP2 sequestration and activation in exosomes secreted by fibroblasts. Considering recent studies suggesting that exosomes are likely vehicles for cell-to-cell signaling and transfer of material between cells,
29–39 clarifying the roles of MMP14 and MMP2 in exosomal transport will have significant implications for understanding the mechanisms of angiogenesis.
Exosomes were isolated using a sucrose density gradient. Wild-type mouse corneal fibroblasts (5 × 107 cells) were seeded onto a 150-mm culture dish with DMEM supplemented with 10% FBS. The next day the cells were washed with phosphate-buffered saline (PBS) and cultured in 1% ultracentrifuged FBS (prepared by ultracentrifugation at 100,000g for 18 hours to exclude bovine exosomes). The conditioned medium was collected and centrifuged at 1500 rpm for 10 minutes and 3000 rpm for 30 minutes to remove cellular debris. The supernatant was then filtered through a 0.45-μm membrane and concentrated using a Millipore concentrator tube (Calbiochem/Millipore) with 100 K MWCO filter. The concentrated conditioned medium was ultracentrifuged at 100,000g for 2 hours. The resulting pellet was resuspended in a 1:200 dilution of Proteinase Inhibitor Cocktail III (Calbiochem/Millipore) in PBS. The pellet was adjusted to 40% sucrose and overlaid with 30% and 5% sucrose. Buoyant-density centrifugation was performed at 100,000g for 18 hours at 4°C in a Beckman SW40Ti or SW60Ti rotor (Beckman Coulter, Inc., Pasadena, CA, USA). Eleven fractions were collected from the top of the gradient.
Exposure of CPAECs, HUVECs, or Normal Corneal Fibroblasts to Exosomes Containing MMP14-YPet or Coculture With MMP14-YPet–Expressing Cells
Wild-type corneal fibroblasts were infected with a retrovirus containing MMP14-YPet. Briefly, pCMMV-MMP14-YPet plasmid was transfected into Phoenix virus packaging cells (American Type Culture Collection [ATCC], Manassas, VA, USA). Secreted virus containing MMP14-YPet was used to infect corneal fibroblasts. Secreted exosomes were isolated from the culture medium of these MMP14-YPet–expressing cells for the reported experiments.
Cover glasses in the wells of a six-well plate were seeded with human umbilical vein endothelial cells (HUVECs), calf pulmonary artery endothelial cells (CPAECs), or normal corneal fibroblasts. For direct exposure to MMP14-YPet–containing exosomes, 1 mL culture medium containing 2 μg isolated exosomes was added to each sample of cultured cells. For coculture with MMP14-YPet–expressing cells, transwells containing corneal fibroblasts overexpressing MMP14-YPet were added to the culture wells. The plate was then incubated for 4 hours, allowing for diffusion of the exosomes to the cells in the bottom dishes. Fluorescence emitted by the exosomes was then observed by confocal microscopy.
In the present study, we found that MMP14 expression is greater in exosomes of corneal fibroblasts than in cell lysate. Our results also demonstrate that corneal fibroblasts can transfer MMP14 protein via exosomes to other cell types, including vascular endothelial cells, which readily take up these exosomes and their contents. Finally, we found that deletion of the MMP14 enzymatic domain leads to an increase in pro-MMP2 accumulation in exosomes, whereas absence of MMP14 results in near-complete failure of MMP2 to localize to exosomes. Our study yields the following significant findings: (1) MMP14 is critically involved in MMP2 localization to exosomes in corneal fibroblasts; (2) exosomes may represent a mechanism for the localization of MMP14 and MMP2 enzymatic activity in the extracellular space; and (3) intercellular transfer of MMP14 and MMP2 between fibroblasts and endothelial cells may occur during angiogenesis and other biological processes.
Research groups including ours have established the ability of exosomes to transfer materials between cells, and this transfer method has implications for processes beyond angiogenesis. For example, enzymatically active MMP14 has been identified in exosomes secreted by fibrosarcoma and melanoma cells,
40 and exosomes may provide a mechanism for intercellular transfer of material in these cell types during the growth and spread of ovarian cancers.
41 However, the mechanisms that control exosomal transport of materials remain unclear. Ligand receptor binding, attachment, and fusion with the target cell membrane or internalization via endocytosis are all posited as possible modes of interaction between exosomes and target cells.
34,36 Regardless of the precise mechanism, exosomes likely require selective targeting of recipient cells to execute the level and specificity of appropriate intercellular transfer and communication currently hypothesized. Through the use of YPet-tagged MMP14, we demonstrated the ability of exosomes to deliver MMP14 to other cells and showed that the efficiency of this delivery varies between different cell types (endothelial cells appeared to accept MMP14-containing exosomes more efficiently than corneal fibroblasts). The differential effects observed for various cell types support the concept of target-specific exosomal activity.
Our data suggest a possible mechanism of MMP14 action in corneal vascularization. We previously demonstrated that MMP14 potentiates multiple processes in FGF2-induced corneal neovascularization,
9 with neovascularization requiring MMP14 activity in the extracellular space to degrade ECM to create routes for endothelial cells to directionally proliferate, migrate, and establish new vessels. However, endothelial cells themselves do not naturally produce substantial amounts of MMP14. Interestingly, corneal fibroblasts produce higher levels of MMP14 that resides in their cell membranes and, as our findings show, in the exosomes they secrete (
Figs. 1,
2). We show that these MMP14-containing exosomes, secreted by fibroblasts, may be the source of endothelial MMP14.
Matrix metalloproteinase 2 is synthesized and secreted as pro-MMP2 in a complex with tissue inhibitor of metalloproteinase-2 (TIMP2). Pro-MMP2 is cleaved by MMP14, releasing activated MMP2. Activated MMP2 degrades basement membrane collagen (type IV), elastin, and several other ECM molecules, including interstitial collagen types I, II, and III, and is associated with ECM remodeling in wound healing, angiogenesis, and tumor invasion.
42 Our finding that MMP2 is carried by exosomes and released by limbal endothelial cells into the extracellular space reveals a possible mechanism by which MMP14 and MMP2 may facilitate the breakdown of ECM in a directional manner toward a wound. Thus, MMP2 may interact with MMP14 in exosomes released by corneal fibroblasts. Therefore, exosomes provide a vehicle by which cells can release MMP14 to directionally modulate endothelial activity and neovascularization.
Our investigation of the roles of MMP14 and MMP2 in exosomes builds upon our understanding of their relationship in the plasma membrane. At the cell surface, MMP14 functions as a receptor for both pro-MMP2 and TIMP2. Matrix metalloproteinase 14 forms a membrane-bound homodimer; one dimerized MMP14 monomer unit also binds TIMP2, which recruits pro-MMP2. The recruited pro-MMP2 is then in position to interact with the other dimerized MMP14.
17 The propeptide of MMP2 is cleaved by MMP14, resulting in an intermediate form, which is subsequently converted to fully active MMP2 through an autocatalytic cleavage. Active MMP2 is then released into the extracellular space.
18,23 Our experiments using MMP14Δexon4 cell cultures show that the dependence of MMP2 activation on MMP14 enzymatic activity is maintained in exosomes. Wild-type corneal fibroblasts contained significant amounts of active MMP2 in exosomes, whereas the loss of MMP14 enzymatic ability led to pro-MMP2 accumulation in exosomes. The finding that MMP14-null corneal fibroblasts produced exosomes with virtually undetectable amounts of pro-MMP2 and no active MMP2 indicates that MMP14 is critically involved in the recruitment of MMP2 to exosomes, although this process does not seem to require the MMP14 enzymatic domain. The interaction of MMP14 in the exosomal packaging of MMP2 is a novel finding and further suggests that exosomes play a key role in the ability of MMP14 to achieve downstream effects in non–MMP14-producing cells. Future research is needed to determine how MMP14 recruits, modifies, and directs MMP2 into and out of exosomes.
In summary, our study demonstrates that exosomes of corneal fibroblasts contain high levels of enzymatically active MMP14 and can deliver their contents to target cells. Although it is clear that MMP14 can modify exosomal levels of MMP2 and significantly impact the transport of MMP2 into exosomes, the exact timing and mechanism of this interaction remain uncertain. More research is needed to characterize the effects of MMP14 transport to recipient cells on physiological and pathological processes. Establishing the potential effects of modulating MMP14 levels will have significant implications for the development of therapeutics targeting angiogenesis in the cornea and other tissues as well as tumor metastasis in many cancers.
Supported by National Institutes of Health Grants EY10101 (DTA) and EY01792 and an unrestricted grant from Research to Prevent Blindness, New York, New York, United States. The authors alone are responsible for the content and writing of the paper.
Disclosure: K.-Y. Han, None; J. Dugas-Ford, None; M. Seiki, None; J.-H. Chang, None; D.T. Azar, Novartis (S), Association for Research in Vision and Ophthalmology (S), Chicago Ophthalmological Society (S), Chicago Medical Society (S)
Egeblad
M,
Werb
Z.
New functions for the matrix metalloproteinases in cancer progression.
Nat Rev Cancer.
2002;
2:
161–174.
Klose
A,
Zigrino
P,
Mauch
C.
Monocyte/macrophage MMP-14 modulates cell infiltration and T-cell attraction in contact dermatitis but not in murine wound healing.
Am J Pathol.
2013;
182:
755–764.
Koenig
GC,
Rowe
RG,
Day
SM,
et al.
MT1-MMP-dependent remodeling of cardiac extracellular matrix structure and function following myocardial infarction.
Am J Pathol.
2012;
180:
1863–1878.
Klein
T,
Bischoff
R.
Active metalloproteases of the A Disintegrin and Metalloprotease (ADAM) family: biological function and structure.
J Proteome Res.
2011;
10:
17–33.
Siefert
SA,
Sarkar
R.
Matrix metalloproteinases in vascular physiology and disease.
Vascular.
2012;
20:
210–216.
Itoh
Y,
Seiki
M.
MT1-MMP: an enzyme with multidimensional regulation.
Trends Biochem Sci.
2004;
29:
285–289.
Azar
DT,
Casanova
FH,
Mimura
T,
Jain
S,
Chang
JH.
Effect of MT1-MMP deficiency and overexpression in corneal keratocytes on vascular endothelial cell migration and proliferation.
Curr Eye Res.
2008;
33:
954–962.
Azar
DT,
Casanova
FH,
Mimura
T,
et al.
Corneal epithelial MT1-MMP inhibits vascular endothelial cell proliferation and migration.
Cornea.
2010;
29:
321–330.
Onguchi
T,
Han
KY,
Chang
JH,
Azar
DT.
Membrane type-1 matrix metalloproteinase potentiates basic fibroblast growth factor-induced corneal neovascularization.
Am J Pathol.
2009;
174:
1564–1571.
Sounni
NE,
Devy
L,
Hajitou
A,
et al.
MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression.
FASEB J.
2002;
16:
555–564.
Zhou
Z,
Apte
SS,
Soininen
R,
et al.
Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I.
Proc Natl Acad Sci U S A.
2000;
97:
4052–4057.
Holmbeck
K,
Bianco
P,
Caterina
J,
et al.
MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover.
Cell.
1999;
99:
81–92.
Albrechtsen
R,
Kveiborg
M,
Stautz
D,
et al.
ADAM12 redistributes and activates MMP-14, resulting in gelatin degradation, reduced apoptosis and increased tumor growth.
J Cell Sci.
2013;
126:
4707–4720.
Shuman Moss LA, Jensen-Taubman S, Stetler-Stevenson WG.
Matrix metalloproteinases: changing roles in tumor progression and metastasis.
Am J Pathol.
2012;
181:
1895–1899.
Deryugina
EI,
Quigley
JP.
Matrix metalloproteinases and tumor metastasis.
Cancer Metastasis Rev.
2006;
25:
9–34.
Irie
K,
Komori
K,
Seiki
M,
et al.
Impaired alveolization in mice deficient in membrane-type matrix metalloproteinase 1 (MT1-MMP).
Med Mol Morphol.
2005;
38:
43–46.
Frittoli
E,
Palamidessi
A,
Disanza
A,
Scita
G.
Secretory and endo/exocytic trafficking in invadopodia formation: the MT1-MMP paradigm.
Eur J Cell Biol.
2011;
90:
108–114.
Osenkowski
P,
Toth
M,
Fridman
R.
Processing shedding, and endocytosis of membrane type 1-matrix metalloproteinase (MT1-MMP).
J Cell Physiol.
2004;
200:
2–10.
Murphy
DA,
Courtneidge
SA.
The “ins” and “outs” of podosomes and invadopodia: characteristics formation and function.
Nat Rev Mol Cell Biol.
2011;
12:
413–426.
Azar
DT,
Chang
JH,
Han
KY.
Wound healing after keratorefractive surgery: review of biological and optical considerations.
Cornea.
2012;
31
(suppl 1):
S9–S19.
Han
KY,
Fahd
DC,
Tshionyi
M,
et al.
MT1-MMP modulates bFGF-induced VEGF-A expression in corneal fibroblasts.
Protein Pept Lett.
2012;
19:
1334–1339.
Sato
H,
Kinoshita
T,
Takino
T,
Nakayama
K,
Seiki
M.
Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2.
FEBS Lett.
1996;
393:
101–104.
Lehti
K,
Lohi
J,
Valtanen
H,
Keski-Oja
J.
Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface.
Biochem J.
1998;
334
(pt 2):
345–353.
Chavez-Munoz
C,
Kilani
RT,
Ghahary
A.
Profile of exosomes related proteins released by differentiated and undifferentiated human keratinocytes.
J Cell Physiol.
2009;
221:
221–231.
Choi
DS,
Kim
DK,
Kim
YK,
Gho
YS.
Proteomics, transcriptomics and lipidomics of exosomes and ectosomes.
Proteomics.
2013;
13:
1554–1571.
Olver
C,
Vidal
M.
Proteomic analysis of secreted exosomes.
Subcell Biochem.
2007;
43:
99–131.
Simpson
RJ,
Jensen
SS,
Lim
JW.
Proteomic profiling of exosomes: current perspectives.
Proteomics.
2008;
8:
4083–4099.
Wubbolts
R,
Leckie
RS,
Veenhuizen
PT,
et al.
Proteomic and biochemical analyses of human B cell-derived exosomes. Potential implications for their function and multivesicular body formation.
J Biol Chem.
2003;
278:
10963–10972.
Regev-Rudzki
N,
Wilson
DW,
Carvalho
TG,
et al.
Cell-cell communication between malaria-infected red blood cells via exosome-like vesicles.
Cell.
2013;
153:
1120–1133.
Ochiya
T,
Lotvall
J.
Exosome as a novel shuttle for innovation. Preface.
Adv Drug Deliv Rev.
2013;
65:
v.
Bang
C,
Thum
T.
Exosomes: new players in cell-cell communication.
Int J Biochem Cell Biol.
2012;
44:
2060–2064.
Camussi
G,
Deregibus
MC,
Bruno
S,
Cantaluppi
V,
Biancone
L.
Exosomes/microvesicles as a mechanism of cell-to-cell communication.
Kidney Int.
2010;
78:
838–848.
Ludwig
AK,
Giebel
B.
Exosomes: small vesicles participating in intercellular communication.
Int J Biochem Cell Biol.
2012;
44:
11–15.
Denzer
K,
Kleijmeer
MJ,
Heijnen
HF,
Stoorvogel
W,
Geuze
HJ.
Exosome: from internal vesicle of the multivesicular body to intercellular signaling device.
J Cell Sci.
2000;
113
(pt 19):
3365–3374.
Valadi
H,
Ekstrom
K,
Bossios
A,
Sjostrand
M,
Lee
JJ,
Lotvall
JO.
Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells.
Nat Cell Biol.
2007;
9:
654–659.
Fevrier
B,
Raposo
G.
Exosomes: endosomal-derived vesicles shipping extracellular messages.
Curr Opin Cell Biol.
2004;
16:
415–421.
Simons
M,
Raposo
G.
Exosomes--vesicular carriers for intercellular communication.
Curr Opin Cell Biol.
2009;
21:
575–581.
Robbins
PD,
Morelli
AE.
Regulation of immune responses by extracellular vesicles.
Nat Rev Immunol.
2014;
14:
195–208.
Buzas
EI,
Gyorgy
B,
Nagy
G,
Falus
A,
Gay
S.
Emerging role of extracellular vesicles in inflammatory diseases.
Nat Rev Rheumatol.
2014;
10:
356–364.
Hakulinen
J,
Sankkila
L,
Sugiyama
N,
Lehti
K,
Keski-Oja
J.
Secretion of active membrane type 1 matrix metalloproteinase (MMP-14) into extracellular space in microvesicular exosomes.
J Cell Biochem.
2008;
105:
1211–1218.
Keller
S,
Konig
AK,
Marme
F,
et al.
Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes.
Cancer Lett.
2009;
278:
73–81.
Vu
TH,
Werb
Z.
Matrix metalloproteinases: effectors of development and normal physiology.
Genes Dev.
2000;
14:
2123–2133.